Skip to main content
Erschienen in: Pediatric Cardiology 3/2024

30.12.2023 | Research

Inpatient Resource Utilization for Hypoplastic Left Heart Syndrome from Birth Through Fontan

verfasst von: Michael Kuntz, Eleonore Valencia, Steven Staffa, Viviane Nasr

Erschienen in: Pediatric Cardiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Completing 3-stage palliation for hypoplastic left heart syndrome requires significant resources. An analysis of recent data has not been performed. We aimed to determine total charges necessary to complete all 3 stages of single-ventricle palliation, including interstage encounters. We also aimed to determine overall resource utilization, including hospital days, interstage admissions, and interstage procedures. We performed a retrospective cohort study using data from the Pediatric Health Information System database between 2016 and 2021, including all patients who completed 3-stage palliation for hypoplastic left heart syndrome. We identified 199 patients who underwent 3-stage palliation of hypoplastic left heart syndrome between 2016 and 2021. Median total adjusted charges (interquartile range, IQR) over the course of 3-stage palliation were $1,475,800 ($1,028,900–2,191,700). Median adjusted charges (IQR) for stage 1, 2, and 3 hospitalizations were $604,300 ($419,000–891,400), $234,000 ($164,300–370,800), and $256,260 ($178,300–345,900), respectively. Median hospital length of stay (IQR) for stages 1, 2, and 3 was 36 (26,53), 9 (6,17), and 10 (7,14) days, respectively. Pulmonary artery stenosis was the most common admitting diagnosis for interstage hospitalizations (3.4% of hospitalizations). Cardiac catheterization (24.1% of procedures) and feeding tube placement (10.0% of procedures) were the most common principal procedures during interstage hospitalizations. Total inpatient charges incurred throughout 3-stage palliation of hypoplastic left heart syndrome are substantial and have risen since prior studies. Gastrointestinal comorbidities and feeding optimization contribute considerably to this resource utilization.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Huang L, Dalziel K, Schilling C, Celermajer D, McNeil J, Winlaw D et al (2017) Hospital costs and cost implications of co-morbid conditions for patients with single ventricle in the period through Fontan completion. Int J Cardiol 240:178–182CrossRefPubMed Huang L, Dalziel K, Schilling C, Celermajer D, McNeil J, Winlaw D et al (2017) Hospital costs and cost implications of co-morbid conditions for patients with single ventricle in the period through Fontan completion. Int J Cardiol 240:178–182CrossRefPubMed
2.
Zurück zum Zitat Zielonka B, Snarr B, Liu M, Zhang X, Mascio C, Fuller S et al (2019) Resource utilization for prenatally diagnosed single-ventricle cardiac defects: a Philadelphia Fetus-to-Fontan cohort study. J Am Heart Assoc 8:e011284CrossRefPubMedPubMedCentral Zielonka B, Snarr B, Liu M, Zhang X, Mascio C, Fuller S et al (2019) Resource utilization for prenatally diagnosed single-ventricle cardiac defects: a Philadelphia Fetus-to-Fontan cohort study. J Am Heart Assoc 8:e011284CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Dean P, Hillman D, McHugh K, Gutgesell H (2011) Inpatient costs and charges for surgical treatment of hypoplastic left heart syndrome. Pediatrics 128(5):e1181–e1186CrossRefPubMedPubMedCentral Dean P, Hillman D, McHugh K, Gutgesell H (2011) Inpatient costs and charges for surgical treatment of hypoplastic left heart syndrome. Pediatrics 128(5):e1181–e1186CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tweddell J, Hoffman G, Mussatto K, Fedderly R, Berger S, Jaquiss R et al (2002) Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation 106(1):I82–I89PubMed Tweddell J, Hoffman G, Mussatto K, Fedderly R, Berger S, Jaquiss R et al (2002) Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation 106(1):I82–I89PubMed
5.
Zurück zum Zitat Pigula F, Vida V, del Nido P, Bacha E (2007) Contemporary results and current strategies in the management of hypoplastic left heart syndrome. Semin Thorac Cardiovasc Surg 19:238–244CrossRefPubMed Pigula F, Vida V, del Nido P, Bacha E (2007) Contemporary results and current strategies in the management of hypoplastic left heart syndrome. Semin Thorac Cardiovasc Surg 19:238–244CrossRefPubMed
6.
Zurück zum Zitat Czosek R, Anderson J, Heaton P, Cassedy A, Schnell B, Cnota J (2013) Staged palliation of hypoplastic left heart syndrome: trends in mortality, cost, and length of stay using a national database from 2000 through 2009. Am J Cardiol 111:1792–1799CrossRefPubMed Czosek R, Anderson J, Heaton P, Cassedy A, Schnell B, Cnota J (2013) Staged palliation of hypoplastic left heart syndrome: trends in mortality, cost, and length of stay using a national database from 2000 through 2009. Am J Cardiol 111:1792–1799CrossRefPubMed
7.
Zurück zum Zitat McHugh K, Hillman D, Gurka M, Gutgesell H (2010) Three-stage palliation of hypoplastic left heart syndrome in the university Healthsystem Consortium. Congenit Heart Dis 5:8–15CrossRefPubMed McHugh K, Hillman D, Gurka M, Gutgesell H (2010) Three-stage palliation of hypoplastic left heart syndrome in the university Healthsystem Consortium. Congenit Heart Dis 5:8–15CrossRefPubMed
8.
Zurück zum Zitat Pinto N, Waitzman N, Nelson R, Minich LL, Krikov S, Botto L (2018) Early childhood inpatient costs of critical congenital heart disease. J Pediatr 203:371–379CrossRefPubMed Pinto N, Waitzman N, Nelson R, Minich LL, Krikov S, Botto L (2018) Early childhood inpatient costs of critical congenital heart disease. J Pediatr 203:371–379CrossRefPubMed
9.
Zurück zum Zitat Hansen J, Madsen N, Bishop L, Morales D, Anderson J (2018) Longitudinal health care cost in hypoplastic left heart syndrome palliation. Pediatr Cardiol 39(6):1210–1215CrossRefPubMed Hansen J, Madsen N, Bishop L, Morales D, Anderson J (2018) Longitudinal health care cost in hypoplastic left heart syndrome palliation. Pediatr Cardiol 39(6):1210–1215CrossRefPubMed
10.
Zurück zum Zitat Kogon B, Kanter K, Alsoufi B, Maher K, Oster M (2015) Outcomes and hospital costs associated with the Norwood operation: beyond morbidity and mortality. Cardiol Young 25(5):853–859CrossRefPubMed Kogon B, Kanter K, Alsoufi B, Maher K, Oster M (2015) Outcomes and hospital costs associated with the Norwood operation: beyond morbidity and mortality. Cardiol Young 25(5):853–859CrossRefPubMed
12.
Zurück zum Zitat Mackie A, Tran D, Marelli A, Kaul P (2017) Cost of congenital heart disease hospitalizations in Canada: a population-based study. Can J Cardiol 33(6):792–798CrossRefPubMed Mackie A, Tran D, Marelli A, Kaul P (2017) Cost of congenital heart disease hospitalizations in Canada: a population-based study. Can J Cardiol 33(6):792–798CrossRefPubMed
13.
Zurück zum Zitat Smith A, Gay J, Patel N (2014) Trends in resource utilization associated with the inpatient treatment of neonatal congenital heart disease. Congenit Heart Dis 9(2):96–105CrossRefPubMed Smith A, Gay J, Patel N (2014) Trends in resource utilization associated with the inpatient treatment of neonatal congenital heart disease. Congenit Heart Dis 9(2):96–105CrossRefPubMed
14.
Zurück zum Zitat Edelson J, Rossano J, Griffis H, Quarshie W, Ravishankar C, O’Connor M et al (2021) Resource use and outcomes of pediatric congenital heart disease admissions: 2003 to 2016. J Am Heart Assoc 10(4):e018286CrossRefPubMedPubMedCentral Edelson J, Rossano J, Griffis H, Quarshie W, Ravishankar C, O’Connor M et al (2021) Resource use and outcomes of pediatric congenital heart disease admissions: 2003 to 2016. J Am Heart Assoc 10(4):e018286CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Anderson B, Ciarleglio A, Cohen D, Lai W, Neidell M, Hall M et al (2016) The Norwood operation: relative effects of surgeon and institutional volumes on outcomes and resource utilization. Cardiol Young 26(4):683–692CrossRefPubMed Anderson B, Ciarleglio A, Cohen D, Lai W, Neidell M, Hall M et al (2016) The Norwood operation: relative effects of surgeon and institutional volumes on outcomes and resource utilization. Cardiol Young 26(4):683–692CrossRefPubMed
16.
Zurück zum Zitat Pasquali S, Jacobs M, He X, Shah S, Peterson E, Hall M et al (2014) Variation in congenital heart surgery costs across hospitals. Pediatrics 133(3):e553–e560CrossRefPubMedPubMedCentral Pasquali S, Jacobs M, He X, Shah S, Peterson E, Hall M et al (2014) Variation in congenital heart surgery costs across hospitals. Pediatrics 133(3):e553–e560CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Furck A, Uebing A, Hansen J, Scheewe J, Jung O, Fischer G et al (2010) Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: a 12-year single-center study. J Thorac Cardiovasc Surg 139(2):359–365CrossRefPubMed Furck A, Uebing A, Hansen J, Scheewe J, Jung O, Fischer G et al (2010) Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: a 12-year single-center study. J Thorac Cardiovasc Surg 139(2):359–365CrossRefPubMed
19.
Zurück zum Zitat Anderson B, Ciarleglio A, Salavitabar A, Torres A, Bacha E (2015) Earlier stage 1 palliation is associated with better clinical outcomes and lower costs for neonates with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 149(1):205–210CrossRefPubMed Anderson B, Ciarleglio A, Salavitabar A, Torres A, Bacha E (2015) Earlier stage 1 palliation is associated with better clinical outcomes and lower costs for neonates with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 149(1):205–210CrossRefPubMed
20.
Zurück zum Zitat ElHassan N, Tang X, Gossett J, Zakaria D, Ross A, Kona S et al (2018) Necrotizing enterocolitis in infants with hypoplastic left heart syndrome following stage 1 palliation or heart transplant. Pediatr Cardiol 39(4):774–785CrossRefPubMed ElHassan N, Tang X, Gossett J, Zakaria D, Ross A, Kona S et al (2018) Necrotizing enterocolitis in infants with hypoplastic left heart syndrome following stage 1 palliation or heart transplant. Pediatr Cardiol 39(4):774–785CrossRefPubMed
21.
Zurück zum Zitat Jeffries H, Wells W, Starnes V, Wetzel R, Moromisato D (2006) Gastrointestinal morbidity after Norwood palliation for hypoplastic left heart syndrome. Ann Thorac Surg 81:982–987CrossRefPubMed Jeffries H, Wells W, Starnes V, Wetzel R, Moromisato D (2006) Gastrointestinal morbidity after Norwood palliation for hypoplastic left heart syndrome. Ann Thorac Surg 81:982–987CrossRefPubMed
22.
Zurück zum Zitat Kelleher S, McMahon C, James A (2021) Necrotizing enterocolitis in children with congenital heart disease: a literature review. Pediatr Cardiol 42(8):1688–1699CrossRefPubMedPubMedCentral Kelleher S, McMahon C, James A (2021) Necrotizing enterocolitis in children with congenital heart disease: a literature review. Pediatr Cardiol 42(8):1688–1699CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat del Castillo S, McCulley M, Khemani R, Jeffries H, Thomas D, Peregrine J et al (2010) Reducing the incidence of necrotizing enterocolitis in neonates with hypoplastic left heart syndrome with the introduction of an enteral feed protocol. Pediatr Crit Care Med 11(3):373–377PubMed del Castillo S, McCulley M, Khemani R, Jeffries H, Thomas D, Peregrine J et al (2010) Reducing the incidence of necrotizing enterocolitis in neonates with hypoplastic left heart syndrome with the introduction of an enteral feed protocol. Pediatr Crit Care Med 11(3):373–377PubMed
24.
Zurück zum Zitat Danford D, Karels Q, Kutty S (2016) Variabilities in the mortality-related resource utilisation for congenital heart disease. Open Heart 3:e000415CrossRefPubMedPubMedCentral Danford D, Karels Q, Kutty S (2016) Variabilities in the mortality-related resource utilisation for congenital heart disease. Open Heart 3:e000415CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Cronk C, Malloy M, Pelech A, Miller R, Meyer S, Cowell M et al (2003) Completeness of state administrative databases for surveillance of congenital heart disease. Birth Defects Res A 67(9):597–603CrossRef Cronk C, Malloy M, Pelech A, Miller R, Meyer S, Cowell M et al (2003) Completeness of state administrative databases for surveillance of congenital heart disease. Birth Defects Res A 67(9):597–603CrossRef
26.
Zurück zum Zitat Schidlow D, Gauvreau K, Patel M, Uzark K, Brown D (2015) Site of interstage care, resource utilization, and interstage mortality: a report from the NPC-QIC registry. Pediatr Cardiol 36(1):126–131CrossRefPubMed Schidlow D, Gauvreau K, Patel M, Uzark K, Brown D (2015) Site of interstage care, resource utilization, and interstage mortality: a report from the NPC-QIC registry. Pediatr Cardiol 36(1):126–131CrossRefPubMed
Metadaten
Titel
Inpatient Resource Utilization for Hypoplastic Left Heart Syndrome from Birth Through Fontan
verfasst von
Michael Kuntz
Eleonore Valencia
Steven Staffa
Viviane Nasr
Publikationsdatum
30.12.2023
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 3/2024
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-023-03372-x

Weitere Artikel der Ausgabe 3/2024

Pediatric Cardiology 3/2024 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.